Tonix Pharmaceuticals
TNXPTNXP · Stock Price
Historical price data
Overview
Tonix Pharmaceuticals is a clinical-stage biotech focused on addressing difficult-to-treat conditions across CNS, immunology, infectious diseases, and rare diseases. Its strategy leverages multiple technology platforms, including a sublingual delivery system, a live virus vaccine platform, and monoclonal antibody development, to advance a broad pipeline. Key near-term catalysts include Phase 2 data for TNX-102 SL in Acute Stress Disorder and the progression of its Phase 2-ready programs in organ transplant rejection and Prader-Willi Syndrome.
Technology Platform
Tonix utilizes multiple tailored technology platforms including a sublingual delivery system for CNS drugs, a live horsepox virus vaccine platform for biodefense, monoclonal antibody development for immunomodulation, and an intranasal potentiation platform for direct nose-to-brain delivery.
Pipeline
37| Drug | Indication | Stage | Watch |
|---|---|---|---|
| TNX-102 SL | Primary Fibromyalgia | Phase 3 | |
| TNX-102 SL 5.6 mg | PTSD | Phase 3 | |
| TNX-102 SL Tablet, 2.8 mg + Placebo SL Tablet | Fibromyalgia | Phase 3 | |
| TNX-102 SL Tablet, 2.8mg + Placebo SL Tablet | Fibromyalgia | Phase 3 | |
| TNX-102 SL + Placebo SL Tablet | PTSD | Phase 3 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Tonix faces established and emerging competitors in each area: CNS (vs. SSRIs, SNRIs, novel psychedelics), immunology (vs. approved biologics and other anti-CD40L programs), rare disease (vs. other oxytocin analogs), and vaccines (vs. approved smallpox/mpox vaccines). Its strategy relies on mechanistic differentiation and targeting niche indications.